STEROID REGULATION OF B-ADRENORECEPTOR GENES IN OBESITY
Project Number3R29DK046793-05S1
Contact PI/Project LeaderCOLLINS, SHEILA
Awardee OrganizationDUKE UNIVERSITY
Description
Abstract Text
The congenital obesity, beta-adrenergic receptor (betaAR) stimulation of
lipolysis and thermogenesis are impaired. Both white and brown
adipocytes express beta1-, beta2-, and beta3AR (the latter is expressed
exclusively in fat). Our preliminary data demonstrate that beta1AR and
beta3AR are impaired in white and brown adipocytes from genetically obese
(ob/ob) mice compared to lean controls. This defect may contribute to
the obese state. In addition, the stimulatory G-protein (Gs) alpha
subunit, to which betaARs are coupled, is depressed in obese animals.
Since elevated corticosteroid (CORT) levels are an essential feature
promoting obesity, and betaAR subtype expression can be modulated by
CORTs, regulation of betaAR subtype gene transcription by this steroid
may be an important component of obesity. There are 4 major aims of this
research plan. (1) Changes in betaAR and Gsalpha will be monitored
during the development of obesity. The mRNA levels of the beta1AR,
beta2AR beta3AR and Gsalpha genes, radioligand binding and beta-agonist-
stimulated adenylyl cyclase activity will be measured in white and brown
adipose tissue from lean and obese mice from 1 week to 14 weeks of age.
Adipocyte-specific markers will also be monitored. (2) The effect of
CORT on expression of betaAR subtypes and Gsalpha genes in brown and
white fat, and their effects on obesity will be assessed in 2 ways: (i)
Adrenalectomized obese mice will be studied over the same developmental
period outlined in Aim 1. (ii) Lean and obese mice will be treated
chronically with the CORT antagonist RU38486 over the same period as in
Aim 1. Results from Aims 1 and 2 will provide a basis for examining more
specific molecular and cellular mechanisms regulating betaAR and Gsalpha
gene expression. (3) Established murine preadipocyte cell lines of white
and brown fat origin will be used to examine the molecular mechanisms
regulating transcription of betaAR subtypes and Gsalpha genes during
adipocyte differentiation and CORT exposure. Nuclear run-on
transcription, mRNA half-life, and cycloheximide sensitivity studies will
determine specific molecular mechanisms responsible for observed changes
in individual betaAR and Gsalpha transcripts. These data will be related
to results obtained from lean and obese mice in vivo in Aims 1 and 2.
(4) Transfection studies with betaAR promoter-reporter constructs in pre-
and differentiated adipocytes are designed to identify regulatory
elements involved in adipocyte differentiation and CORT regulation of
betaAR transcription. Together, these integrated studies should more
directly define the physiological, cellular and molecular mechanisms
regulating betaAR signal transduction in adipocytes during the
development of obesity.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
044387793
UEI
TP7EK8DZV6N5
Project Start Date
01-July-1998
Project End Date
30-June-2000
Budget Start Date
01-July-1998
Budget End Date
30-June-2000
Project Funding Information for 1998
Total Funding
$25,036
Direct Costs
$23,416
Indirect Costs
$1,620
Year
Funding IC
FY Total Cost by IC
1998
National Institute of Diabetes and Digestive and Kidney Diseases
$25,036
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3R29DK046793-05S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R29DK046793-05S1
Patents
No Patents information available for 3R29DK046793-05S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R29DK046793-05S1
Clinical Studies
No Clinical Studies information available for 3R29DK046793-05S1
News and More
Related News Releases
No news release information available for 3R29DK046793-05S1
History
No Historical information available for 3R29DK046793-05S1
Similar Projects
No Similar Projects information available for 3R29DK046793-05S1